Volume 31, Issue 51
Heterocyclic Compounds
Full Access

ChemInform Abstract: Human β3-Adrenergic Receptor Agonists Containing 1,2,3-Triazole-Substituted Benzenesulfonamides.

Linda L. Brockunier

Linda L. Brockunier

Dep. Med. Chem., Merck Res. Lab., Rahway, NJ 07065, USA

Search for more papers by this author
et al. et al.

et al. et al.

Dep. Med. Chem., Merck Res. Lab., Rahway, NJ 07065, USA

Search for more papers by this author
First published: 31 May 2010

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

ChemInform Abstract

Different substitution patterns of the triazole ring are explored with preference of 2,4-disubstitution. The prepared compounds (IV) and (X), in which fluorinated aromatic rings are substituted for aliphatic side chains, are analogues of potent and selective β3-adrenergic receptor agonists. The new agonists show markedly improved oral bioavailabilities while maintaining potency, selectivity, and in vivo efficacy. In particular, compound (X), which is an exceptionally selective human β3-agonist, reveals 6500- and 1500-fold selectivity over binding to β1 and β2 receptors, respectively.

chemical structure image

    The full text of this article hosted at iucr.org is unavailable due to technical difficulties.